Q3 FY2024 Financial Results

February 6, 2025

Financial Results

Kazuo Koshiji

Chief Financial Officer

Q3 FY2024 Overview

Solid progress versus FY forecast. Overseas business absorbed impacts of *Diquas LX* and other factors
Increased year-end dividend, considering mid-to long term earnings prospects

Q3 FY2024 results

- Revenue: -0.0% YoY (JPY 222.8 billion) / 74% vs FY forecast
- Core OP: -11.4% YoY (JPY 43.7 billion) / 79% vs FY forecast
- Net profit attributable to owners of the company: +3.2% YoY (JPY 27.5 billion) / 85% vs FY forecast

Business update

- *Diquas LX*: Root cause identification and countermeasures progress. Preparing to consult authorities
- Mid-to long term growth: STN1012700 (myopia) approval and STN1013800 (ptosis) filing in Japan

FY2024 forecast

- Forecast: Solid progress, no change in forecast considering swing seasonal factor related to pollen
- Dividend: Increased year-end dividend to JPY 19, equivalent to JPY 36 per share annually.
  Forecast JPY 38/share for FY2025 based on progressive dividend policy

	Q3 FY2023 ACT	Q3 FY2024 ACT
USD (JPY)	143.61	152.63
EUR (JPY)	155.60	164.96
CNY (JPY)	20.07	21.33

YoY increase in net profit

(JPY billions)	Q3 FY2023 Actual	Q3 FY2023 vs Revenue	Q3 FY2024 Actual	Q3 FY2024 vs Revenue	Q3 FY2024 YoY
Revenue	222.8	-	**222.8**	**-**	**-0.0%**
Cost of sales	91.4	41%	97.6	44%	+6.8%
Gross profit	131.4	59%	**125.1**	**56%**	**-4.8%**
SG&A expenses	64.1	29%	64.7	29%	+1.0%
R&D expenses	18.0	8%	16.8	8%	-7.1%
Core operating profit	49.3	22%	**43.7**	**20%**	**-11.4%**
Non-core expenses	1.0	0%	-	-	-100.0%
Amortization on intangible assets associated with products	7.1	3%	6.6	3%	-6.3%
Other income	1.4	1%	0.4	0%	-71.9%
Other expenses	6.4	3%	2.2	1%	-65.5%
Operating profit	36.2	16%	**35.2**	**16%**	**-2.7%**
Finance income	1.3	1%	1.4	1%	+8.9%
Finance expenses	1.0	0%	1.3	1%	+34.1%
Share of loss of investments accounted for using equity method	2.9	1%	-	-	-100.0%
Profit before tax	33.6	15%	35.3	16%	+5.2%
Income tax expenses	7.0	3%	8.0	4%	+14.1%
Actual tax ratio	*21%*	-	*23%*	-	+1.7pt
Net profit	26.6	12%	**27.3**	**12%**	**+2.9%**
Net profit attributable to owners of the company	26.6	12%	27.5	12%	+3.2%
Core net profit	39.6	18%	33.8	15%	-14.7%

Major factors in YoY differences

Revenue: -0.0%

- Overseas business (China, Asia and EMEA) : +9%, +3% excluding FX

Gross profit: -4.8%

- Increased COGS ratio mainly due to region/product mix

Core OP: -11.4%

- SG&A: Absorbed FX impact and almost flat to previous year
- R&D expenses: Decrease mainly from clinical trials status quo and cost optimizations

OP (IFRS): -2.7%

- Completed structural reforms previous FY. Related expenses decreased

Net profit (IFRS): +2.9%

- No share of loss of investments YTD
- Tax ratio excluding one-time factors: 21.1%

Q3 FY2024 Sales bridge

Flat YoY: Product supply impact mitigated by solid progress from other products in Japan and EMEA including one-time revenue



Japan	-5.0% YoY: Minimized impact from NHI price revision and *Diquas LX* voluntary recall with other products. *Sentei-ryoyo* (new system of co-pay hikes from Oct. 2024) impacts within initial FY expectations
China	+2.3% YoY (Ex. FX impact -3.7%): Solid performance from multi-channel strategy and *Tapros.* Negatively impacted by *Diquas* VBP, and product supply (approx. JPY -1.3 billion YoY)
Asia	+1.5% YoY (Ex. FX impact -2.0%): Steady growth from mainstay products in glaucoma and dry eye in key markets. Negatively impacted by product supply (approx. JPY -0.4 billion YoY) and HCP strikes in South Korea
EMEA	+14.8% YoY (Ex. FX impact +9.1%): Continued growth from glaucoma preservative-free and new products as well as dry eye products. Includes one-time revenue from out-licensing

*Sales classified into countries or regions based on customer's location. EMEA: Europe, Middle East and Africa

Minimized *Diquas LX* impact with cost optimization and one-time revenue



Regional contribution profits	Japan Dry eye products: Mainly due to decrease in revenue from *Diquas LX* voluntary recall and NHI price revision, coupled with *Diquas LX* recall related expenses (FY2024 NHI price revision *Diquas*: -32%, *Hyalein 0.1*: -10%) Others: Steady progress in other therapeutic areas, and decrease in SG&A Overseas (including FX) China: Maintained profit despite impact from *Diquas* VBP and product supply Asia: Increased profit despite product supply and other factors EMEA: Solid progress with increased profit coupled with one-time revenue from out-licensing
Others	Increased expenses with FX. Positive impact from completion of structural reforms including streamlining in Americas pharmaceutical commercial business

1 R&D and back-office expenses in region and global functions, and contribution profit not related to the regions above

	FY2023 ACT	FY2024 FCST (Aug.6)
USD (JPY)	144.80	155.00
EUR (JPY)	156.88	165.00
CNY (JPY)	20.24	21.30

Faster-than-expected progress

(JPY billions)	FY2023		FY2024			
	Actual	vs Revenue	Forecast (Aug. 6)	vs Revenue	YoY	Q3 Progress
Revenue	302.0	-	**302.0**	**-**	**+0.0%**	**74%**
Cost of sales	123.1	41%	129.0	43%	+4.8%	76%
Gross profit	178.9	59%	**173.0**	**57%**	**-3.3%**	**72%**
SG&A expenses	90.8	30%	91.0	30%	+0.2%	71%
R&D expenses	25.3	8%	27.0	9%	+6.9%	62%
Core operating profit	62.8	21%	**55.0**	**18%**	**-12.4%**	**79%**
Non-core expenses	1.0	0%	-	-	-100.0%	
Amortization on intangible assets associated with products	9.5	3%	8.8	3%	-7.1%	
Other income	1.5	1%	0.7	0%	-54.8%	
Other expenses	15.3	5%	2.4	1%	-84.3%	
Operating profit	38.5	13%	**44.5**	**15%**	**+15.5%**	**79%**
Finance income	1.6	1%	2.0	1%	+27.2%	
Finance expenses	2.7	1%	1.5	0%	-43.7%	
Share of loss of investments accounted for using equity method	7.6	3%	-	-	-100.0%	
Profit before tax	29.9	10%	45.0	15%	+50.6%	78%
Income tax expenses	3.2	1%	11.5	4%	+262.6%	
Actual tax ratio	*11%*	-	*26%*	-	-	
Net profit	26.7	9%	**33.5**	**11%**	**+25.5%**	**82%**
Net profit attributable to owners of the company	26.6	9%	32.5	11%	+22.0%	85%
ROE	9%		11%			
Core ROE	16%		14%			
Core net profit	48.5	16%	41.3	14%	-15.0%	82%

Factors to consider for FY forecast

- Japan: Pollen-levels
- Overseas: Material FX fluctuations
- Cost optimization
- FYE fluctuations in sub-Core items

Increased year-end dividend to JPY 19 based on progressive dividend policy

- Dividend raised considering mid-to long term prospects in earnings
- Approx.16% / JPY 79.0 billion of OTSD shares repurchase since FY2022



(FY)	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024FCST
Total return ratio (IFRS)	38%	19%	106%	30%	76%	46%	120%	47%	-	106%	152%
Share buy-back (JPY billions)	-	-	12.3	-	13.9	-	-	-	25.7	16.2	37.1 (completed)

R&D Update

Peter Sallstig

Chief Medical Officer

Final stages before launch – Myopia approved and Ptosis filed
Existing area: Multiple milestone achievements on late stage pipelines

New area	Atropine sulfate STN10**127**00/01 *RYJUSEA Mini*	Myopia	Received **approval** in Japan **Filed** in March 2024 in Europe **Started preparations for filing** in Asia
	Oxymetazoline hydrochloride STN10**138**00	Ptosis	**Filed** in Japan Achieved **FPI**[1] in P3 trial in Europe
	AFDX0250BS STN10**134**00	Myopia	Achieved **LPO**[2] in P2a trial in Japan
Existing area	Latanoprost cationic emulsion STN10**130**01 *Catiolanze*	Glaucoma	**Filed** in Asia
	Netarsudil mesylate STN10**139**00 *Rhopressa®/Rhokiinsa®*	Glaucoma	**Confirmed long-term safety and efficacy** in P3 (long-term treatment) trial in Japan
	Epinastine hydrochloride (twice a day, eye drop) STN10**114**03	Allergic conjunctivitis	**Achieved primary endpoints** in P3 trial in China
	Omidenepag isopropyl STN10**117**02 *Eybelis Mini*	Glaucoma	Achieved **FPI** in P3 trial in China
	Netarsudil mesylate /latanoprost STN10**140**03 *Rocklatan®/Roclanda®*	Glaucoma	**Started preparations for P3 trial** in Japan

1 FPI：First Patient In. 2 LPO：Last Patient Out

Received approval for *RYJUSEA Mini* ophthalmic solution 0.025%, Japan's first ophthalmic solution for slowing myopia progression

Planning to launch in April-May 2025 as a drug not listed in the National Health Insurance Drug Price Standard. Selling price for patients is set by each medical institution due to out-of-pocket treatment.

Contributing to resolving the social issue concerning increasing prevalence of myopia in children by providing products and information based on scientific knowledge as a company specialized in ophthalmology

- *RYJUSEA Mini* ophthalmic solution 0.025%

  - Typically, one drop per use, once a day before bedtime
  - Single-dose unit
  - Preservative-free formulation
  - Although there are no explicit age restrictions, it is primarily intended for children
- Information on diseases, diagnosis and treatment

School

Visual acuity test at annual checkup



Medical Institution

Examination & diagnosis
- Confirming eligible patients

Initiation of treatment

1st visit after initiation
- 1 week-1 month after prescribing

Subsequent visits after initiation
- Every 3-6 months after prescribing

Treatment end date considerations
- It is desirable to continue treatment until late teens.

This shows the generally expected flow based on the environment in Japan and the IMI Clinical Myopia Management Guidelines Report provided by the International Myopia Institute. In practice, it may vary depending on the patient's condition and the doctor's judgment.

Myopia: STN10**127**01 (atropine sulfate, SYD-101)

Filed in Europe in March 2024 with P3 data which met primary endpoint. Expecting to receive approval early in FY2025

Confirmed statistically significant lower annual progression rate (primary endpoint) and change from baseline in spherical equivalent of 0.01% and 0.03% STN1012701 (SYD-101) compared to placebo at Month 24. Safety and tolerance confirmed for 0.01% and 0.03% STN1012701.

Primary endpoint

Annual progression rate of myopia at month 24 (diopter/year)

	Placebo	0.01% STN1012701	0.03% STN1012701
LS mean rate	-0.44	-0.31	-0.32
95% CI	-0.50, -0.38	-0.37, -0.25	-0.38, -0.26
P-value	NA	0.0003	0.0009

Change from baseline in spherical equivalent (diopter)



Change from baseline in axial length (mm) *<50% sites collected AL Data



- Showed numerically better effect of 0.01% and 0.03% STN10**127**01 compared to placebo on axial length change (not powered statistical significance).
- The most frequently reported treatment-emergent adverse event at 24 Months was photophobia (Placebo: 16.7%, 0.01% STN10**127**01: 24.1%, 0.03% STN10**127**01: 30.4%).
- This study (STAR study) was designed to continue for a total of 48 months and is estimated to be completed in the summer of 2025.

Epinastine hydrochloride designed formulation for China, twice-daily eye drop, achieved primary endpoints on pivotal trial (P3)

Demonstrated non-inferiority of STN1011403 compared to *Alesion LX* and 0.1% olopatadine hydrochloride at Day 15 on both primary endpoints, ocular itching score and bulbar conjunctival hyperemia score change from baseline and confirmed safety and tolerance. STN1011403 for China market is a reformulated version of *Alesion LX*, a twice-daily eye drop sold in Japan and South Korea.

Ocular Itching Score

Change from baseline in the most severe ocular itching score within 24 hours



LS mean differences between groups at Day 15 (95% confidence interval)

	Alesion LX	0.1% Olopatadine HCl
STN10**114**03	0.05（**-0.11, 0.21**）	0.05（**-0.12, 0.21**）

Non-inferiority margin: **0.5**

Bulbar Conjunctival Hyperemia Score

Change from baseline in bulbar conjunctival hyperemia score



LS mean differences between groups at Day 15 (95% confidence interval)

	Alesion LX	0.1% Olopatadine HCl
STN10**114**03	-0.10（**-0.24, 0.03**）	-0.03（**-0.16, 0.10**）

Non-inferiority margin: **0.4**

Appendix

Revenue and contribution profit by region



Note) Contribution profit: Deducting cost of sales and expenses related to revenue generation from regional revenue.
Regional revenue related to regional business are used to calculate contribution profit and regional revenue may differ from revenue (location basis) in the above chart.
Reorganization in overseas in FY2023 reflects to contribution profits in FY2023 and FY2024.

Q3 FY2024 revenue by region

Consolidated

(JPY billions)	Q3 FY2023 (Ref.)	Q3 FY2024
EYLEA[1]	56.2	60.3
Cosopt	19.2	20.4
Alesion[2]	11.6	15.8
Others	135.8	126.2
Total	222.8	222.8



Japan

(JPY billions)	Q3 FY2023 (Ref.)	Q3 FY2024
EYLEA[1]	56.2	60.3
Alesion[2]	11.5	15.6
Diquas (including Diquas LX)	16.4	4.9
Others	41.9	38.8
Total	126.0	119.7



China

(JPY billions)	Q3 FY2023 (Ref.)	Q3 FY2024
Cravit	7.0	7.0
Hyalein	6.3	6.7
Diquas	2.8	2.1
Others	6.5	7.2
Total	22.6	23.1



Asia

(JPY billions)	Q3 FY2023 (Ref.)	Q3 FY2024
Cosopt	5.1	5.3
Hyalein	2.5	2.9
Cravit	2.7	2.2
Others	11.7	11.9
Total	21.9	22.3



EMEA

(JPY billions)	Q3 FY2023 (Ref.)	Q3 FY2024
Cosopt	10.9	13.0
Ikervis	8.4	6.8
Tapros	6.2	6.6
Others	23.8	30.2
Total	49.3	56.6



*Including one-time revenue from license out in “Others”

Revenue in each region (Q3 FY2024)



*Ratio excluding one-time revenue from license out

Intravitreal VEGF inhibitor | Glaucoma/Device | Dry eye | Allergy | Bacterial conjunctivitis | Others

1 Co-promoted product of Bayer Yakuhin, Ltd. (MAH), including *EYLEA* 8mg
2 *Alesion*: Trademark of alliance partner, Boehringer Ingelheim KG, including *Alesion LX* and *Alesion* eyelid cream

Sentei-ryoyo (new system of co-pay hike from Oct. 2024) impact:
Revenue and forecast (within expectations)

Listed 17 products[1] (including different strength products, as of Feb. 2025) and consists of 5-6% in Japan business.
Anticipate some more products to be listed including *Diquas*, *Tapros*, *Tapcom* and *Alesion LX* which GEs have been launched

(JPY millions)

Product	Therapeutic area	FY2021	FY2022	FY2023	FY2024 Q1	FY2024 Q2	FY2024 Q3	FY2024 YTD	FY2024 FCST
Cosopt [2]	Glaucoma	5,047	4,039	3,347	814	716	510	2,040	2,111
Alesion (4 times/day)	Allergy	4,440	2,987	1,807	219	202	146	568	786
Hyalein 0.1/0.3 [2]	Dry eye	5,800	4,949	4,268	1,031	1,130	915	3,077	3,590
Cravit 0.5/1.5	Bacterial conjunctivitis	1,754	1,285	1,126	234	212	127	572	674
Timoptol XE 0.25/0.5	Glaucoma	3,092	2,807	2,445	434	416	346	1,197	1,550
Timoptol 0.25/0.5	Glaucoma								
Alegysal	Allergy								
Livostin	Allergy								
Flumetholon 0.1	Others								
Santeson 0.02/0.1	Others								
Sancoba	Others								
Mydrin-M	Others								
Total		20,134	16,067	12,994	2,732	2,677	2,045	7,454	8,710
Japan business total		173,633	177,373	175,608	40,553	38,876	40,231	119,660	160,649
Ratio vs Japan business total		11.6%	9.1%	7.4%	6.7%	6.9%	5.1%	6.2%	5.4%

1 Only eye drops 2 Unit-dose products excluded

Healthy financial position maintained. Reduce assets to improve ROE, ROIC



Status of intangible assets related to products and goodwill



Status of intangible assets amortization related to products



ROE, Core ROE, ROIC

FY	2019	2020	2021	2022	2023	2024 (FCST)
Core ROE	12%	12%	11%	11%	16%	14%[1]
ROE	8%	3%	8%	-	9%	11%[1]
ROIC	11%	5%	12%	-	16%	17%[2]

1 Including share buy-back 2 Including factoring

Cash flow



1 Treasury shares through open-market repurchase

Foreign exchange rate assumptions and sensitivities

FX rate

(JPY)

	FY2023 Actual	FY2024 Forecast (No change from Aug.6)	FY2024 vs FY2023	Q3 FY2023 Actual	Q3 FY2024 Actual	Q3 FY2024 vs Q3 FY2023
USD	144.80	155.00	107.0%	143.61	152.63	106.3%
EUR	156.88	165.00	105.2%	155.60	164.96	106.0%
CNY	20.24	21.30	105.2%	20.07	21.33	106.3%

Sensitivities

Impact of a 1% depreciation of the yen
(vs FY2024 revised forecast rate on August 6)

(JPY billions)

	Total[1]	USD	EUR	CNY
Revenue	+1.3	+0.06	+0.66	+0.32
Core OP	+0.2	-0.03	+0.09	+0.06
OP (IFRS)	+0.1	-0.04	+0.07	+0.05

1 Total: impacts from USD, EUR, CNY and other major currencies (rounding to nearest 100 million)

FX impact on Q3 FY2024 (vs Q3 FY2023)

(JPY billions)

	Total
Revenue	+5.1
Core OP	+0.7
OP (IFRS)	+0.5

Segment: Market size
Graph: Market share (change from last year)

Prescription ophthalmic market in Japan （Jan. 2024 - Dec. 2024）

Total: JPY 360.6 bil



Glaucoma: JPY 81.2 bil



Retinal disorders*: JPY 140.6 bil



Corneal/dry eye: JPY 34.0 bil



Allergy: JPY 50.2 bil



Anti-infection: JPY 5.8 bil



*Including co-promoted product (Anti-VEGF *EYLEA*, *EYLEA 8mg*) of Bayer Yakuhin, Ltd. (MAH). Based on Santen Pharmaceutical (distributor) records.

Source: Copyright © 2025 IQVIA. JPM 2023.1-2024.12; Santen analysis based on IQVIA data. Reprinted with permission.

Current status of global development (1)

As of January 2025
Updated information is in blue

Glaucoma and ocular hypertension area

Indication	Generic Name	Dev. Code	Development Status[1]	
Glaucoma	Tafluprost / timolol maleate (combination) *Tapcom / Taptiqom*	STN10**111**01 DE-111A	China	Filed *Plan: FY2024 approval*
	Omidenepag isopropyl *Eybelis Mini*	STN10**117**02	China	Started P3 in November 2024 *Plan: FY2026 P3 completion*
	Sepetaprost	STN10**126**00 DE-126	US	P2 (met primary endpoint)
			Japan	Filed *Plan: FY2025 approval*
			Europe	P2 (exploratory study) completion
	Latanoprost *Catiolanze*	STN10**130**01 DE-130A Catioprost	Europe	Launched
			Asia	Filed in November 2024 *Plan: FY2026 approval*

1 Only projects for which the study protocols were approved in-house are shown,

Current status of global development (2)

As of January 2025
Updated information is in blue

Glaucoma and ocular hypertension area

Indication	Generic Name	Dev. Code	Development Status	
Glaucoma	Netarsudil mesylate *Rhopressa®/Rhokiinsa®*	STN10**139**00 AR-13324	Japan	P3 (Met primary endpoints in pivotal trials and confirmed long-term safety and efficacy) *Plan: FY2025 filing*
			Europe	Launched
			Asia	Launched
	Netarsudil mesylate /latanoprost (combination) *Rocklatan®/Roclanda®*	STN10**140**03	Japan	*Plan: FY2024 P3 start*
		STN10**140**00 PG-324	Europe	Launched
			Asia	Approved *Plan: FY2024 launch*

Current status of global development (3)

As of January 2025
Updated information is in blue

Keratoconjunctival disease area including dry eye

Indication	Generic Name	Dev. Code	Development Status	
Vernal keratoconjunctivitis	Ciclosporin *Verkazia*	STN10**076**03 DE-076C	China	Approved
Dry eye	Diquafosol sodium (long-acting) *Diquas LX*	STN10**089**03 DE-089C	Japan	Launched
			Asia	Received approval in March 2024 but deregistered product license in August 2024 in South Korea
	Olodaterol hydrochloride	STN10**141**00	Japan	P1/2a (met primary endpoint), planning late-stage clinical trials
Fuchs endothelial corneal dystrophy	Sirolimus (eye drop)	STN10**109**04[1]	US France India	P2a *Plan: FY2025 P2a completion*
Meibomian gland dysfunction	Sirolimus (eye drop)	STN10**109**05	Japan	An additional P2a *Plan: FY2025 additional P2a completion*
Allergic conjunctivitis	Epinastine HCl (eyelid cream)	STN10**114**02	Japan	Launched
	Epinastine HCl (twice a day, eye drop)	STN10**114**03	China	P3 (met primary endpoints) *Plan: FY2025 filing*

1 Santen retains the option right for exclusive license of this program. Santen development code to be formally assigned to the product when Santen obtains exclusive license upon the completion of Phase II trial.

Current status of global development (4)

As of January 2025
Updated information is in blue

Refractive disorder

Indication	Generic Name	Dev. Code	Development Status	
Myopia	Atropine sulfate *RYJUSEA Mini*	STN10**127**00 DE-127	Japan	Approved in December 2024 *Plan: FY2025 launch*
			China	P2/3 *Plan: FY2026 P2/3 completion*
			Asia	P2 (met primary endpoint) *Plan: FY2025 filing*
		STN10**127**01 SYD-101	Europe	Filed in March 2024 *Plan: FY2025 approval*
	AFDX0250BS	STN10**134**00	Japan	P2a *Plan: FY2024 P2a completion*
			China	P1 (confirmed safety and tolerability)

Current status of global development (5)

As of January 2025
Updated information is in blue

Others

Indication	Generic Name	Dev. Code	Development Status	
Ptosis	Oxymetazoline hydrochloride	STN10**138**00 RVL-1201	Japan	Filed in December 2024 *Plan: FY2025 approval*
			Europe	Started P3 in December 2024 *Plan: FY2025 P3 completion*
			China	P3 *Plan: FY2026 P3 completion*
			Asia	*Plan: FY2026 filing*
Retinitis pigmentosa	jCell	STN**60001**00	-	jCyte Planning P3

Pivotal P3 trial protocol in Europe and US (NCT03918915)



This study (STAR study) was designed to continue for a total of 48 months and is estimated to be completed in the Summer of 2025.

Pivotal P3 trial protocol in China

Multicenter, randomized, observer-masked, active control Phase III study to evaluate the efficacy and safety of STN10**114**03 ophthalmic solution in Chinese patients with allergic conjunctivitis



Both eyes, twice a day (8:00 ± 2 hours, 20:00 ± 2 hours), one drop for each eye

Forward-looking statements

- Materials and information provided in this announcement include so-called "forward-looking statements" .The earnings forecasts and other forward-looking statements herein are based on information currently available to the Company and certain assumptions that we believe to be reasonable. The realization of these forecasts is subject to various risks and uncertainties. Please be aware that actual results could differ materially from these forward-looking statements. We assume no obligation to update the contents of this document from time to time.
- Risk factors include, but are not limited to, the following:
  External factors such as trends in pharmaceutical administration, social and economic conditions, changes in laws and regulations, and exchange rates. Changes in the competitive environment, such as the impact of generics. Reliance on certain products and business partners, such as dependence on mainstay products, reliance on licensed products, and reliance on certain business partners for the supply of bulk drugs. Uncertainty in the development of new drugs, the possibility that R&D investment will not produce sufficient results, the success or failure of alliances with other companies, and other R&D activities. Other factors include intellectual property rights, production slowdowns and delays caused by natural disasters, product supply issues such as discontinuations and product recalls, litigation, and risks related to global business development.
- This document contains information about pharmaceutical products (including products under development) but is not intended for advertising or medical advice.
- The purpose of this document is to disclose information that serves as a reference to investors, and it does not constitute a solicitation or recommendation for investment. You should make investment decisions based on your own judgment.
- The information contained in this document is subject to change without notice. The use of these materials is the responsibility of the user, and we assume no responsibility for any damages caused by the use of these materials, including errors in the stated information.